GUANZE MEDICAL (02427) Fa Ying Guang estimates that shareholders should account for no more than 45 million yuan in losses in the medium term

According to Zhitong Finance App, GUANZE MEDICAL (02427) announced that it is expected that the Group will obtain losses attributable to company owners of not more than RMB 45 million in the six months ending June 30, 2026, while profit attributable to company owners for the six months ending June 30, 2025 is approximately RMB 3.4 million. According to the Board of Directors, the expected loss is mainly due to: (i) the decline in gross profit due to increased sales of medical imaging products and the provision of medical imaging cloud services (these two businesses have lower gross margin), while reducing software sales (software has higher gross margin); (ii) increased depreciation of fixed assets taken into account sales costs, administrative expenses, and sales and distribution expenses; (iii) increased R&D expenses; and (iv) increased share-based payment expenses confirmed by share rewards attributable in February 2026 due to changes in controlling shareholders.